Cancer-fighting virus plus immunotherapy shows promise in advanced tumors

NCT ID NCT06214143

Recruiting now Disease control Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a modified herpesvirus (T3011) combined with standard immunotherapy drugs (PD-1/PD-L1 inhibitors) in people with advanced solid tumors that have not responded to other treatments. The goal is to see if the combination is safe and can shrink tumors. About 68 participants will receive the treatment, and researchers will monitor side effects and tumor response.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Locations

Anyang Cancer Hospital
RECRUITING

Anyang, China
Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center
RECRUITING

Shenzhen, China
Dongguan People's Hospital
RECRUITING

Dongwan, China
Fujian Cancer Hospital
RECRUITING

Fuzhou, China
Guangxi Medical University Affiliated Cancer Hospital
RECRUITING

Nanning, China
Harbin Medical University Cancer Hospital
RECRUITING

Ha’erbin, China
Henan cancer hospital
RECRUITING

Zhengzhou, China
Hunan cancer hospital
RECRUITING

Changsha, China
Jiangxi cancer hospital
RECRUITING

Nanchang, China
Liaoning Cancer Hospital
RECRUITING

Shenyang, China
Shandong cancer hospital
RECRUITING

Jinan, China
Shanghai East Hospital
RECRUITING

Shanghai, China
Shanghai Ninth People's Hospital
RECRUITING

Shanghai, China
Shanxi Cancer Hospital
RECRUITING

Taiyuan, China
Sichuan Cancer Hospital
RECRUITING

Chengdu, China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
RECRUITING

Guangzhou, China
The First Affiliated Hospital of Bengbu Medical University
RECRUITING

Bengbu, China
The First Affiliated Hospital of Guangdong Pharmaceutical University
RECRUITING

Guangzhou, China
The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITING

Hangzhou, China
The Second Affiliated Hospital of Zhejiang University School of Medicine
RECRUITING

Hangzhou, China
Tianjin cancer hospital
RECRUITING

Tianjin, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITING

Wuhan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.